IGC Pharma AI Stock Analysis
Want to see IGC full AI Analyst Report?
IGC Pharma (IGC) AI Stock Analysis
IGC Pharma
(NYSE MKT:IGC)
The score is held down primarily by very weak financial performance—extreme negative margins and continued cash burn—despite some TTM revenue improvement and a low/zero-debt balance sheet. Technicals add pressure with a clear downtrend (price below key moving averages and negative MACD). Valuation provides limited support because the negative P/E reflects ongoing losses and no dividend yield data is available.
IGC Pharma (IGC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $23.21M
- Dividend Yield
- ―
- Average Volume (3M)
- 698.61K
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 0.75
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 70
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
IGC Pharma Business Overview & Revenue Model
Company Description
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aime...
How the Company Makes Money
IGC is a clinical-stage drug developer, so its ability to generate recurring commercial revenue depends primarily on successfully advancing drug candidates through clinical trials and obtaining regulatory approvals, after which it could earn revenue...
IGC Pharma Financial Statement Overview
Summary
Overall fundamentals are weak. Revenue is small but improving (~12.2% TTM), and losses narrowed versus 2024, but profitability remains extremely poor (TTM EBIT margin ~-469%, net margin ~-644%) with ongoing cash burn (TTM FCF about -$5.23M). A key offset is a comparatively safer balance sheet for a loss-making biotech (zero TTM debt and positive equity).
Income Statement
22NegativeBalance Sheet
62PositiveCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.26M | 1.19M | 1.27M | 1.34M | 911.00K | 397.00K |
| Gross Profit | 208.00K | 352.00K | 619.00K | 733.00K | -158.00K | 194.00K |
| EBITDA | -7.78M | -6.49M | -6.50M | -12.36M | -10.85M | -14.37M |
| Net Income | -8.11M | -6.55M | -7.12M | -13.00M | -11.51M | -15.02M |
Balance Sheet | ||||||
| Total Assets | 9.73M | 9.19M | 8.75M | 9.90M | 17.18M | 26.83M |
| Cash, Cash Equivalents and Short-Term Investments | 413.00K | 235.00K | 405.00K | 1.20M | 3.35M | 10.46M |
| Total Debt | 869.00K | 926.00K | 241.00K | 345.00K | 481.00K | 611.00K |
| Total Liabilities | 3.23M | 3.06M | 2.42M | 2.58M | 2.27M | 2.94M |
| Stockholders Equity | 6.50M | 6.12M | 6.33M | 7.32M | 14.91M | 23.89M |
Cash Flow | ||||||
| Free Cash Flow | -5.59M | -6.11M | -5.28M | -5.71M | -7.67M | -8.23M |
| Operating Cash Flow | -5.21M | -5.94M | -4.79M | -5.20M | -7.05M | -7.46M |
| Investing Cash Flow | -845.00K | -192.00K | -442.00K | -317.00K | -235.00K | -742.00K |
| Financing Cash Flow | 5.37M | 5.93M | 4.45M | 3.52M | 100.00K | 4.14M |
IGC Pharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Negative. The current price of 0.20 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.25, and below the 200-day MA of 0.28, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.67 is Neutral, neither overbought nor oversold. The STOCH value of 73.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IGC.
IGC Pharma Risk Analysis
IGC Pharma disclosed 37 risk factors in its most recent earnings report. IGC Pharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksIGC Pharma Peers Comparison
Overall Rating
ELUT47Neutral
VRCA47Neutral- IGC44Neutral
DYAI41Neutral
PLUR27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ELUT | 47Neutral | $41.32M | 0.72 | 267.71% | ― | -52.81% | 7.54% |
| VRCA | 47Neutral | $60.47M | -2.25 | -444.44% | ― | 106.21% | 79.84% |
| IGC | 44Neutral | $22.87M | -2.42 | -123.93% | ― | ― | ― |
| DYAI | 41Neutral | $14.66M | -1.82 | -2918.10% | ― | -8.05% | -14.12% |
| PLUR | 27Underperform | $14.12M | -0.49 | 144.63% | ― | -23.95% | 30.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IGC | Igc Pharma, Inc. | 0.20 | -0.16 | -44.38% | |
| PLUR | Pluri Inc. | 1.20 | -2.98 | -71.29% | |
| DYAI | Dyadic International Inc. | 0.39 | -0.52 | -57.13% | |
| VRCA | Verrica Pharmaceuticals | 3.91 | 0.04 | 1.03% | |
| ELUT | Elutia Inc. | 0.92 | 0.18 | 23.99% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026